Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS G12V |
Therapy | RAF265 + Trametinib |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS G12V | urinary bladder cancer | sensitive | RAF265 + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, RAF265 and Mekinist (trametinib) combination treatment inhibited colony formation compared to RAF265 alone in cultured cells harboring HRAS G12V (PMID: 34554931). | 34554931 |
PubMed Id | Reference Title | Details |
---|---|---|
(34554931) | RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. | Full reference... |